LONDON, UK: Graft Polymer (UK) plc announced the signing of a manufacturing service agreement with a prominent partner in the Israeli pharma market, including GPL acting as a lead contract manufacturing organization (‘CMO’).
Under the agreement, Graft Polymer is to provide manufacturing services from its GraftBio production facility in Slovenia, which is now fully operational. Graft Polymer has been contracted by the partner to produce its patented haemostatic powder following a recent, successful pilot scheme.
The customer has an innovative product whose manufacturing requires deep-seated understanding of and experience with polymers. The benefits of the product are its ability to change from a self-emulsifying powder to a gel on contact with blood, meaning that it can penetrate a wound and clot the blood effectively from within.
As such, it has a wide range of applications and Graft Polymer will work with our partner to enhance the product in due course, leveraging its SNEDDS (self-nanoemulsifying drug delivery system) technology.
The benefits of this service agreement to Graft Polymer are:
- Leveraging the company’s GraftBio production facility to produce bio polymers as drug delivery systems for the pharma industry and allowing GPL to become a formal CMO.
- Harnessing GPL’s strong R&D capabilities for further development of the haemostatic product.
- Delivering a new material revenue stream for GraftBio.
- Evidence of cost effectiveness and fast delivery capabilities.
This pioneering product, developed by Professor Danny Baranes from Ariel University, is a haemostatic agent which effectively stops minor to severe bleeding. Catering to a wide range of needs and applications, the product is intended use in emergency medical services, tactical and security sectors, and military medical settings, as well as for personal wound care.
The Partner has a firm commitment to enhancing healthcare outcomes and is dedicated to making significant contributions to developing haemostasis and wound care solutions.
Commenting on the agreement, Graft Polymer CEO & CTO Victor Bolduev said: “This represents a significant opportunity for the Company’s Graft Bio division, and evidence of our strong innovation capabilities in producing medical device products for the pharma industry”.